ฝึกพูดภาษาอังกฤษด้วยเทคนิค Shadowing จากวิดีโอ: CumbriaMed Research Webinar Series: Obesity
เลือกโหมดฝึก
แต่ละโหมดจะเปิดห้องฝึกแบบเต็มจอ
446 ประโยค
หากประโยคสั้นหรือยาวเกินไป กดที่ Edit เพื่อปรับแก้
1
Good afternoon.
2
I'm Jonathan Weber, and I welcome you to the latest webinar from the Cumbria Med Research Webinar Series.
3
We're a collaboration of the new Pears Cumbria School of Medicine in Cumbria with our partners,
4
Imperial College London, the University of Cumbria, and North Cumbria Integrated Care and HS Trust, NCIC.
5
And we aim to bring webinars on aspects of importance and topicality in medical research,
6
bringing experts from Imperial College together with local practitioners in Cumbria to talk about those aspects of medicine
7
which we believe are important to all of us here. So welcome.
8
So without further ado, I'd like to introduce our first speaker today on obesity,
9
and that's Professor Tricia Tan from Imperial College London.
10
She is a professor of endocrinology and also a consultant physician in endocrinology at Imperial College Healthcare NHS Trust,
11
and was part of the group led by her mentor Steve Bloom,
12
who really first identified some of the actions of the GLP -1 agonist on obesity.
13
Tricia, over to you.
14
Hi, Jonathan.
15
Thanks for this kind invite.
16
And I'm going to get straight to the talk.
17
Let's just get this out.
18
So just to check, can everyone see this?
19
Yeah, we can see the slides.
20
You can see the slides.
21
Brilliant.
22
Okay.
23
Well, first, thanks for the kind introduction.
24
I'm going to talk to you today about actions of GLP -1 on appetite.
25
And I'm sure everyone, you know, has heard about all the drugs that are currently available with Govis and Tazepatide.
26
And I hope today's talk, we will cover a little bit on the background, starting first on why we treat obesity,
27
where pharmacological treatment fits in.
28
I will give you a brief review on GLP -1 and its development,
29
some clinical evidence for their use in obesity and associated conditions,
30
and then just a little bit about future drugs on the horizon.
31
so why do we want to treat obesity well one in four adults in the uk are obese
32
and obesity we now know are associated with multiple comorbidities
33
and we've listed over 200 plus the common ones include diabetes
34
fatty liver disease heart disease high blood pressure arthritis obstructive sleep apnea associated with anxiety, depression, and cancer.
35
So if you look at this person, the well -known person on the right, he had obesity, died at the age of 55,
36
had edema, likely due to heart failure, leg ulcers, chronic ulceration infections, and likely to have been diabetic.
37
He also had disability and was not able to walk or stand.
38
So obesity is not a cosmetic problem.
39
It is disabling and causes premature death.
40
For many years, we have only had lifestyle and diet,
41
which essentially leads to around 3 % to 8 % weight loss.
42
But the problem we have is that with diet and lifestyle, it's often not sustainable.
43
And then we see this yo -yoing of the weight over time.
44
Then on the other spectrum we had bariatric surgery which remains very effective.
45
It's a procedure that leads to long -term sustained weight loss
46
and improvement in diabetes but it is really not a treatment option for everyone.
47
And then what how about in between?
48
Well for many years we didn't really have anything.
49
We had olistat which you have led to only maybe 2 -3 % weight loss, but with lots of side effects.
50
Since the development of GLP -1 agents,
51
we now have drugs that actually can bridge this gap between lifestyle and surgery.
52
And we're going to talk a little bit more about this.
53
GLP -1 is a hormone that is secreted from our gut, from the L cells, and it's secreted after eating.
54
Our gut will sense the nutrients, and the hormone secreted from our gut then signals to different areas,
55
including the pancreas, the beta cells, to stimulate insulin release, and this brings blood sugars down.
56
It also counter -regulates other hormones, such as glucagon, which is known to push blood sugars up.
57
And the GLP -1 can also act directly on the appetite centers in the brain.
58
So this therefore then triggers fullness and reduction in appetite.
59
As I mentioned, this is a naturally occurring hormone.
60
And the hormone itself that secreted only last for a few minutes in circulation.
61
So what pharma companies have done over the last 20 years is that they have engineered and re -engineered the hormones.
62
The hormones made up of, it's a peptide hormone, so made up of natural amino acids, so making it more resistant to break down by enzymes,
63
and also adding something like a fatty acid tail here.
64
And you can see this is semaglutide and tizepatide, where this then prolongs the half -life of the drugs.
65
So now we're on to basically the third generations of these drugs.
66
And the drugs can be given as injections and tablets.
67
GLP -1, we have all been talking about this for the last year or so,
68
lots in the media, but actually it's been around for 20 years.
69
We've been using this to treat patients with type 2 diabetes
70
and due to its beneficial effects of increasing insulin secretion and suppressing glucagon secretion.
71
And on average, it's been shown to be effective in reducing the HbA1c,
72
which is a way that we monitor the long -term control of diabetes by 1 .4 to 2 .1%,
73
and also has the advantage over drugs like insulin and the sulfonylureas without significant hypoglycemia risk,
74
so low blood sugars.
75
But when used for treating people with type 2 diabetes,
76
on average, we only see around five plus kilogram weight loss with the diabetes doses of the drug.
77
But we have shown clear benefits in type 2 diabetes for cardiovascular disease,
78
chronic kidney disease, heart failure, and stroke prevention.
79
So this data has been generated for many years now.
80
And examples of the earlier GLP ones includes exanatide,
81
dulaglutide, but now more commonly people are using semaglutide or otherwise known as azempic, and also the oral version, which is ribelsius.
82
And all these drugs for diabetes have been recommended.
83
by NICE and other guidelines for treatment of diabetes,
84
particularly for atherosclerotic patients with atherosclerotic cardiovascular disease and chronic kidney disease.
85
How about obesity?
86
Well, the trials really came out in the last six to seven years,
87
And I'm going to now just take you through some of the key trials on the newer generations of GLP -1.
88
Semaglutide, which is also used for type 2 diabetes, but known as a Zempic, but when used for treating obesity,
89
it's called Wigovi, but they're the same drugs.
90
For diabetes, we use one milligram weekly, but for the treatment of obesity,
91
we use 2 .4 milligrams weekly.
92
So basically, over the years, the trials have escalated the dose of the GLP -1.
93
And you can see here that inpatients living with obesity but without diabetes,
94
we achieved much better weight loss of around 15 kilograms over 68 weeks.
95
How about tazepatide?
96
Well, tazepatide, the same, initially licensed for treating diabetes, now also licensed for obesity.
97
SUMOUT -1 trial is one of the pivotal trials.
98
Tazepatide is a GLP -1 agent, but it is also a dual agonist.
99
So it basically not just acts on the GLP -1 receptor, but it also acts on the GIP receptor,
100
which is also an incretin hormone.
101
GIP is also released naturally from the gut together with GLP -1.
102
So it's thought to have a double action and the double actions thought to increase insulin secretion after eating.
103
So technically targeting better glucose control and possibly also better appetite suppression.
104
But the thing about GIP is that there's some interesting biology, which we still don't fully understand.
105
But the thinking is that it has effects on our fat tissue,
106
our adipocytes, increasing the breakdown of the fats and hence also improving glucose and fat clearance.
107
And you can see here from the Surmount -1 trial that the terzepatite at around 68 weeks,
108
you know, results in about 20 percent weight loss.
109
And the extension study over three years have shown that if you stay on the high dose,
110
you continue to maintain this weight loss over three years.
111
And what's also really important here is if you look at the graph down here,
112
if you are on the drug and you have pre -diabetes or risk of development,
113
diabetes will very much suppress the development of diabetes from 15 % in placebo towards 1 % to 2 % over time.
114
and um surmount five trial it's a trial
115
that uh came out a few months ago essentially
116
it's a head -to -head trial of tezapatide at its top
117
dose 10 to 15 milligrams versus semaglutide 2 .4 milligrams
118
and this essentially shows that tezapatide uh can achieve around six percent better weight loss than Wigovi or semaglutide.
119
But Novonordis, who develops semaglutide,
120
then came back with a higher dose study, what they call the step -up trial,
121
where they then showed that actually if you increase the semaglutide dose to 7 .2 milligrams,
122
you can also achieve even better weight loss with an additional approximately 3 % weight loss.
123
So that essentially covers the weight loss side.
124
But when we look at these drugs, we need to be thinking about other goals apart from weight loss.
125
And there are many trials that have explored this, and I won't have time to go through them,
126
but here is a table that essentially summarizes some of the benefits of GLP -1 outside weight loss.
127
And this is a summary of randomized controlled trials.
128
You can see here that there's now trial data showing improvements in diabetes, prevention of development of diabetes in people with pre -diabetes,
129
cardiovascular disease, heart failure, fatty liver disease, chronic kidney disease, obstructive sleep apnea, and even peripheral vascular disease.
130
I will now take you through some of these key trials, just highlighting some of the key findings.
131
So the select randomized controlled trial essentially is a trial using semaglutide 2 .4 milligrams in patients living with obesity
132
and with pre -existing cardiovascular disease, a study over four years.
133
And this study showed over 20 % reduction in major adverse cardiovascular endpoints,
134
which is very exciting.
135
And you can see here also on the graph on the right
136
that the primary cardiovascular composite endpoint curves actually separates very early on within three to six months of being on the drug.
137
So even before we achieve significant weight loss.
138
And to also compare the SELECT trial to the STEP1 trial, which was the obesity trial,
139
patients in the SELECT trial only lost on average about 10 % weight loss so indicating here that there are
140
weight loss independent mechanisms that is happening here with the use of these drugs.
141
And as you can see on this list here on the left -hand side, it's not only reduced mace, but also all -cause death,
142
development of kidney disease, development of diabetes, and risk of heart failure hospitalization and urgent visits.
143
the mechanisms that you know
144
that it's currently sort of being postulated behind some of these
145
benefits is sort of multiple sort of contributions really from amelioration of high glucose to reduction in postprandial hyperlipidemia
146
because the drugs also lead to reduction in chylomicron assembly in the gut.
147
And if you have a dual agent with the GIP, there's a reduction in adipose uptake of lipids.
148
The GLP -1 also leads to reduction in inflammation, which are drivers of atherosclerosis.
149
And there is also a direct effect on myocardium leading to protection from ischemia.
150
And at the same time,
151
there is also a natriotic effect of the drugs leading to diuresis and contribution to reduction in blood pressure.
152
But not to forget, with the reduction in weight, patients also become more active and more mobile.
153
And this also leads to better health outcomes.
154
So moving on, we will now talk a little bit about fatty liver disease, otherwise known as MASL or MASH,
155
and both semaglutide
156
and tazepatide have been trialed in patients with biopsy -confirmed metabolic dysfunction associated steatohepatitis
157
and fibrosis stage 2 and 3 versus placebo -controlled.
158
And both trials basically have shown resolution of the steatohepatitis and without worsening of the liver fibrosis,
159
and also evidence of improvement in liver fibrosis.
160
So this is very exciting.
161
And from the heart failure perspective,
162
again, both drugs have been assessed in patients with heart failure with preserved ejection fraction.
163
And as you can see here, both led to improvement in symptoms,
164
symptom scores, and tazepatide also showed a reduction in the adjudicated death from CV disease.
165
Moving on to obstructive sleep apnea.
166
Well, I've just highlighted this trial here, which is from Tizapati.
167
Again, significant improvement in obstructive sleep apnea symptom scores.
168
And there's also been similar study data for other GLP -1 agents, but they're much smaller study,
169
so I've not highlighted it.
170
So there is an overall class effect.
171
In terms of chronic kidney disease, well, we're still awaiting definitive trials in the non -diabetic people with obesity.
172
But these trials here, the FLOW trial, essentially is a trial in patients with diabetes,
173
have shown favorable effects on composite kidney outcomes, onset of kidney failure, greater than 50 % reduction in EGFR,
174
death from kidney -related OCV causes.
175
And this is, as mentioned, in the context of type 2 diabetes and CKD2 and 3 and microalbuminuria. And equally,
176
the post hoc analysis of the SELECT trial also demonstrated favorable effects in kidney outcomes in people without type 2 diabetes.
177
So to round this off, I think I just wanted to talk a little bit about
178
sort of the weight loss effects versus the direct effects of these drugs.
179
And it's often difficult, but it's something that we need to think about when we start using these drugs in the clinic,
180
because it may not always be due to the weight loss benefits as shown in the SELECT trial.
181
And Navid Sitar and all put together this paper,
182
which essentially tried to weigh out whether it's a weight loss effect,
183
which we think is related to reduction in fat mass, mechanical loading, versus the direct effects on organs,
184
where, for instance, leading to increased insulin secretion, anti -inflammatory effects, endothelial effects, reduction in lipids, reduction in blood pressure,
185
etc. So if we go back to the comorbidities that we discussed,
186
the conditions where we think weight loss has bigger benefits versus direct effects include things like joint problems,
187
osteoarthritis, obstructive sleep apnea, fatty liver disease,
188
hypertension, and heart failure versus the conditions where you've got atherosclerotic cardiovascular disease
189
and type 2 diabetes the thinking is that there's more to it than just weight loss.
190
There's a direct benefit.
191
And something like CKD, we think more of a balance effect.
192
And certainly this is something to think about a little bit more in terms of when considering treatments for these patients.
193
So I hope I've given you a quick overview on the broad use of these drugs.
194
I'm now going to just quickly take you through what else is on the horizon.
195
So multi -agonist hormone as a treatment strategy is something that is currently the next exciting thing,
196
really, and basically using GLP -1 as a backbone.
197
OK, and this essentially is something that actually at Imperial we've been working on for many years.
198
And we've done sort of many experimental human studies where we've shown that combining hormones,
199
this actually results to not one plus one benefit, but actually synergistic effect.
200
And if you look at bariatric surgery as a model, you can see that post -bariatric surgery,
201
patients secrete three to four times higher levels of combinations of these gut hormones.
202
So using those principles, we've shown that combining, for instance, GLP -1 and glucagon,
203
this not only leads to reduction in food intake, you get more reduction than when using a single hormone,
204
but you also get an increase in energy expenditure.
205
And this is important because when we lose weight, we metabolically adapt.
206
So how you burn energy drops.
207
But if you have a drug that can then keep that energy expenditure at a good level,
208
it can actually prevent the more rapid weight regain.
209
So these are the principles that I think the next generation combination hormones will be thinking about.
210
And here are just some examples of some of the combination studies that we've shown.
211
And with the human studies that we've done, it essentially has shown that multi -agonism is an acceptable strategy.
212
So what's on the horizon?
213
Well, first, the GLP -1 plus glucagon is very much sort of close to becoming licensed and available.
214
Quite a few early development of these combination drugs I'd like to also mention have discontinued,
215
but these are the drugs that are currently still in place,
216
suvidutide and mastutide, sort of completed or in phase three phase.
217
And actually, in fact, mastutide is now approved for use in China.
218
And the idea behind here, as mentioned, is synergistic appetite suppression, increased energy expenditure.
219
And the other thing to mention is having glucagon on board means there's a direct effect on fat clearance in the liver.
220
Retrotrutide, which is an Eli Lilly compound, is actually very exciting.
221
It combines GLP -1, glucagon, and GIP.
222
And the data to date shows that it's achieving even better weight loss than to zapatite,
223
up to 24 % over 48 weeks in people with obesity.
224
And in people with diabetes, more than 2 % drop in HbA1c,
225
which is quite significant, and also improved weight loss over the other trials, about 17 % reduction.
226
Prisha, I need to encourage you to wind up.
227
To wind up?
228
Okay, will do.
229
So the next is just to mention, there's also GLP -1 plus amylin.
230
Again, exciting combinations.
231
So combinations, so far, preliminary data showing better weight loss.
232
This other drug here is a GLP -1 and GIP antagonist,
233
okay, and extremely sort of confusing, really, within the field.
234
But again, you know, all that agonist and antagonist both working as well
235
and certainly it's something
236
that in the field lots of people including us at imperial are trying to unpick
237
but here this drug here is interesting because you may be able to use this once monthly
238
okay and then of course there are the oral agents ribelsius semaglutide but for obesity you'd be higher dose, 50 milligrams versus diabetes.
239
And Ophaglipron is a small molecule.
240
So it's not peptide based.
241
It's easier to take.
242
And data as shown here, you know, fairly good weight loss, you know, not as good as injections, but good enough.
243
Okay.
244
So I think just to sum up, These drugs are exciting.
245
They do have side effects, but we know that the side effects can gradually reduce over time,
246
and there are ways that you can mitigate this by slower dosing
247
and slower dose escalations but real world data have shown
248
that adherence is low so more than 50 percent people using database study mainly us
249
and outside uk data have shown
250
that more than 50 percent people discontinue treatment after a year
251
but i think this could reflect either side effects or the fact
252
that the drugs are expensive
253
and people are having to pay for this in the uk unfortunately it's sad to say
254
that there's inequality of access okay very few people in the nhs currently can access
255
and people who can access the treatment
256
you know need to be able to afford between three to five hundred pounds per month
257
and to summarize we have these very effective drugs in use they're exciting.
258
I hope I've shown you that these drugs bring many benefits,
259
but in the long run they make no good if we're not able to use these drugs for people living with obesity.
260
Obesity is clearly recognized as a key driver of multiple morbidity
261
and we need to have proper funding
262
and treatment for these drugs uh to be prioritized thank you sorry
263
if i overran thank you trisha
264
so without further ado i'm going to introduce dr ashara ranatunga from ncic based down in white haven
265
at uh west cumberland hospital dr ranatunga hi yes
266
okay so um thank you for the kind introduction
267
and i will be talking about obesity is it the next pandemic
268
and the role of a tier 3 weight management service today this is my topic outline
269
and when we are talking about obesity it is important
270
that we understand the scale of the issue what is obesity who is affected and what are the complications of the disease
271
Obesity is a complex relapsing condition with multiple causes and significant implications for health.
272
It has health implications at every stage across the life course from pregnancy through to childhood and adulthood.
273
And as my colleague mentioned, living with obesity increases the risk of developing chronic diseases, including type 2 diabetes, heart disease,
274
many cancers, liver and respiratory diseases.
275
So, this is the prevalence of overweight and obesity data from the Health Survey for England 2021.
276
You can see almost 6 out of 10 women and 7 out of 10 men were having overweight and obesity.
277
And if we only look at the obesity data, 3 out of 10 women and 2 out of 10 men were living with obesity.
278
This is the distribution according to gender, on the top graph you can see the women, and on the bottom graph you can see the men,
279
so according to the age distribution as well, and again you can see starting from early adulthood up until late adulthood,
280
the prevalence of both overweight and obesity is quite high, indicating that it has affected the working population,
281
in turn affecting the productivity of the country.
282
This is the prevalence of obesity on the top graph
283
and prevalence of overweight and obesity on the bottom graph according to the year.
284
So you can see again it has gradually increased over time.
285
This is the prevalence of overweight and obesity according to the geographical distribution
286
and you can see living in north of England we have very high prevalence of both overweight and obesity.
287
Before talking about the management of obesity, it is important to understand the etiology of obesity.
288
It is a complex multifactorial disease which has a complex interplay between many factors,
289
biological, behavioral and environmental.
290
Biological factors such as genetics, brain gut axis which is the communication between the brain and the intestinal tract,
291
prenatal determinants such as pre -pregnancy weight of the mother and the maternal weight gain during pregnancy,
292
stages of our life such as pregnancy, menopause, hormonal conditions such as underactive thyroid,
293
Cushing's disease, certain medications such as antidepressants,
294
antipsychotics, physical disability, gut microbiome and certain viruses such as adenoviruses can lead to weight gain.
295
Behavioral factors such as excessive calorie intake, eating patterns, sedentary lifestyle, reduced physical activity,
296
insufficient sleep and smoking cessation are some of the factors that can contribute to weight.
297
Environmental factors such as food abundance,
298
built environment is the environment which has component of social and physical determinants,
299
socio -economic status, cultural factors, bias and discrimination and certain environmental chemicals can also lead to weight gain.
300
As we all as we discussed before obesity is associated with multiple metabolic conditions.
301
In this graph I have summarized that
302
so you can see due to accumulation of fat tissue there's release of certain chemicals including inflammatory adipokines,
303
cytokines and chemokines which in turn lead to vascular endothelium dysfunction which can lead to diseases such as hypertension,
304
fatty liver disease and type 2 diabetes.
305
With further progression of the disease there's development of chronic kidney disease and cardiovascular disease and beyond that some cancers.
306
before
307
when we are discussing about the management of obesity as we discussed before the disease itself is multifactorial in origin
308
so it is important that we approach the management in a multidisciplinary manner
309
so exercise both resistant training
310
and aerobic exercise can lead to a fat tissue loss dietary changes such as low carbohydrate diet low fat diet
311
and high fiber diet can lead to weight loss.
312
Bariatric surgery procedures such as gastric banding,
313
gastric bypass, duodenal switch and sleeve gastrectomy can lead to weight loss by reducing energy intake,
314
by altering gut hormones and gut microbiota.
315
Healthy gut microbiota can also lead to weight loss.
316
The ways that we can modify that is by changing our dietary habits, by doing physical exercise and undergoing bariatric surgery,
317
consumption of prebiotic, symbiotic and probiotics.
318
Psychological management also plays a key part including behavioral therapy.
319
It is important in weight loss as well as maintaining the lost weight.
320
With regard to the weight loss medications my colleague explained in detail the available options
321
and how they work and future treatment options such as micro RNA might have a place in the future.
322
So these are the available anti -obesity medications we discussed about liraglutide,
323
semaglutide and tersepatide which is the newest medication that is available for us.
324
Coming into weight management services, what are weight management services?
325
They are multi -component programs that aim to reduce a person's energy intake,
326
improve their dietary health and help them to be more physically active by changing their behavior.
327
There are different levels or tiers of weight management services and these different tiers cover different aspects.
328
This is the structure of the weight management services in UK.
329
Tier 1, it includes preventive services, which are dietary advice, physical activity, and behavioral changes.
330
Tier 2 services include lifestyle, multi -component weight management, and both
331
Tier 1 and Tier 2 services are provided by local authorities.
332
Tier 3 service is the specialist multidisciplinary weight management service, and Tier 4 service is more or less similar to Tier 3,
333
but in addition, patients can undergo bariatric surgery if they are eligible.
334
Both Tier 3 and Tier 4 services are provided by local commissioning groups.
335
So as healthcare providers and some of the patients who are listening to this,
336
and especially the commissioners who are providing funding for the weight management services, it is important we understand why we have to invest in weight management.
337
Studies have shown
338
that a moderate weight loss of 5 -10 % of body weight is associated with reduction in blood pressure and cholesterol,
339
improved control of blood sugar and reduced incidence of type 2 diabetes, reduction in chronic conditions such as osteoarthritis of the knee,
340
hepatic steatosis and non -alcoholic fatty liver disease.
341
Weight loss can lead to improvement in quality of life,
342
depression, mobility, sexual dysfunction and urinary stress incontinence and it can improve the symptoms of polycystic ovary syndrome and infertility in women.
343
There's also reduction in the incidence of cancers and overall reduction in healthcare costs and mortality.
344
And studies have also shown that interventions with best evidence of success include the following elements.
345
They address both eating and physical activity.
346
They provide well -established behavior change techniques such as specific goal setting, relapse prevention and self -monitoring.
347
They encourage the development of social support in the plan changes and include a strong focus on maintenance.
348
Coming to tier 3 weight management service, it is a clinician -led multidisciplinary team,
349
potentially including a physician, specialist nurse, specialist dietitian, psychologist, psychiatrist and a physiotherapist.
350
They provide non -surgical intensive weight management with medical therapy with an MDT approach.
351
This is the structure of the tier three weight management service at North Cumbria Integrated Care NHS Foundation Trust.
352
Our core clinical group is formed by a bariatric physician,
353
dietician, physiotherapist, CBT therapist and a psychologist.
354
We provide eight weeks of weekly group education
355
and one -to -one consultations to the needy patients
356
and we signpost the patients for further support if needed and we provide onward specialist referrals as well.
357
Once the patients complete the tier 3 weight management service
358
they will be eligible to be referred to tier 4 weight management service if they're eligible.
359
In parallel to this co -clinical pathway we have our medical pathway where we prescribe weight loss medications
360
and it runs from 12 months to 24 months.
361
These are our entry criteria for the tier 3 weight management service which I will not go into detail.
362
At NCIC we provide eight weeks of group sessions.
363
We initially provide an introductory session where the patients go through everything
364
that we provide as a brief introduction and thereafter they can opt into the service to undergo the eight -week course.
365
We follow the NICE guidelines.
366
We offer practical and safe advice about physical activity and healthy eating.
367
We use evidence -based behavioral change techniques, provide ongoing motivation, motivational support and follow -up.
368
We aim a target weight loss of 5 to 10 %
369
of body weight at a realistic pace of 0 .5 to 1 kilogram per week.
370
And it's just beyond 3 years since our inception.
371
These are some of our data.
372
3 ,745 patients have been referred to us
373
and we have accepted 3 ,274 patients our average patient has a weight of 129 .7 kilograms
374
and a BMI of 46 .2
375
so they are severely obese these are our referral trend
376
you can see over time the number of referrals has gradually increased
377
this is the distribution of our referral according to the age group
378
Again, you can see majority of our referrals are to young to late adults.
379
This is the distribution of referrals according to the geographical area, and majority of our referrals are from Carlisle.
380
This is the distribution of referrals according to the deprivation index, and you can see majority of our referrals are coming from highly deprived areas.
381
We have 2 ,836 females in our service and 16 patients with learning difficulties.
382
These are some of our outcome data.
383
What I would like to bring your attention to is the average weight loss.
384
Average weight loss post group is 2 .45%.
385
At six months, it is 5 .56%.
386
6%.
387
And at 12 months, it's 6 .5%, indicating that we have met our targets.
388
And we have referred 83 patients to tier 4 weight management service, and most of them have already undergone bariatric surgery.
389
These are some of our data from the medical pathway.
390
We have started 50 patients on liraglutide, which is succenda.
391
At three months, our patients had 10 .3 % weight loss.
392
At six months, 15 .7 % weight loss.
393
At 12 months, 16 .3 % weight loss.
394
I don't have any data from our VGOVI patients because we recently started it.
395
And we have plans to start test hepatite in the near future.
396
In this graph, you can see in addition to the weight loss, our patients had improved HbA1c depicted from the red line
397
and liver enzymes depicted from the orange line and the cholesterol depicted from the gray line.
398
These are our patient feedback data as shown in the green area
399
you can see majority of our referral have been majority of our feedback have been really good.
400
I would like to finish my presentation with the story of
401
Mr. Alan Smith who is a 69 year old gentleman from Cockermouth.
402
He was diagnosed with prediabetes, hypertension, osteoarthritis, atrial fibrillation when he was referred to us.
403
He lost 28 .6 kilograms which account 20 .4 percent at 12 months.
404
His HbA1c normalized.
405
He came off most of the antihypertensive medications.
406
He would like to say a few words as well.
407
Hello, my name is Alan.
408
I was diagnosed as a borderline diabetic, so I was referred to a diabetic consultant.
409
I went through the benefits of weight loss to help
410
and alleviate years my condition i suggested tier 3 weight management and a 12 -week course to lose weight
411
i was skeptical at first as i've tried every day for
412
the past 50 years always yo -yoing back back again
413
so i joined the tier 3 weight management journey back in september 2022 right from the word go i knew
414
that this was different the organizational backup the consultant physio dietitian and the psychologist kept you on track
415
the support was something I had not experienced doing other weight loss weight loss journeys
416
it took a few weeks to get into the mindfulness
417
part of the course but the team helped cajoled and with an expert to move you along at a pace
418
I'd run it out of a saxophone daily injections after 5 weeks
419
these were a godsend helped me to come to terms with my eating habits.
420
Expressing my need to eat, I went down from 3 ,500 calories a day to 1 ,500.
421
After 12 weeks, I reached a good one. Would I manage?
422
Would I cope?
423
The answer was yes.
424
The weight dropped off me.
425
Initially, I have lost five and a half stones.
426
The words of psychologists still kick in, along with a dietician whose examples of when and what to eat.
427
The change in my lifestyle has been dramatic.
428
The diet base has gone.
429
I am fitter, more active and ideally achieved 10 ,000 steps.
430
I'd like to buy a new wardrobe to give me more chance than what I'd buy.
431
I had nothing but praise for the Tier 2 -3.
432
And thoroughly and wholeheartedly recommend
433
Tier 3 suits to anyone.
434
But at the end of the year, if you don't change, nothing changes.
435
It's in your own hands.
436
The programme will work if you want it to.
437
Thanks again Tier 3.
438
Thank you very much.
439
Bye.
440
This is the Tier 3 wage management service team at NCIC.
441
Thank you.
442
Thank you, Dr. Ranatunga.
443
That was excellent.
444
Come to the end of the webinar.
445
Can I thank most sincerely, Trisha Tan and Nishaya Ratatunga for their excellent presentations.
446
Thank you.
ดาวน์โหลดแอป
ทุกอย่างที่ต้องใช้เพื่อพูดได้คล่อง
AI ให้คะแนนการออกเสียงให้คะแนนทุกประโยค
ฝึก IPAเชี่ยวชาญทุกเสียง
คำศัพท์สร้างคลังคำของคุณ
เกมคำศัพท์เล่นไปเรียนไป
FOR YOU
วิดีโอแนะนำ
C143 ประโยค
The Science of Obesity: Regeneron’s Research on Genetics, GLP-1s, and Quality Weight Loss
Daily ConversationUniversity Students
C11
655 ประโยค
Nature-based Solutions in action: Lessons from the energy and water sectors
Daily ConversationUniversity Students
C12
61 ประโยค
Abdominal Examination - OSCE Guide (Latest) | UKMLA | CPSA | PLAB 2
Daily ConversationUniversity Students
C11
284 ประโยค
Why do people smoke?
Daily ConversationUniversity StudentsWorking Adults
C11
653 ประโยค
How We Incorporate Patient Priorities Care into Our Clinical Pharmacy Practices
Daily ConversationUniversity StudentsWorking Adults
C183 ประโยค
Advanced Level English Conversation ESL TOEIC Part 1 - The Global Obesity Epidemic
Daily ConversationUniversity StudentsWorking Adults
C11
214 ประโยค
2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease
Daily ConversationUniversity Students
C11
746 ประโยค
Blindboy discovers the link between gut health and mental health
Daily ConversationUniversity StudentsWorking Adults
C12
179 ประโยค
PARP Inhibitors: 2023 Updates
Daily ConversationUniversity Students
C1255 ประโยค
Olivia
Daily ConversationUniversity Students
C11
154 ประโยค
Sequential, Multiple Assignment, Randomized Trial Designs With Dr Kidwell
Daily ConversationUniversity StudentsWorking Adults
C11
287 ประโยค
Lecture 12: Retina, Part 2: Retinal vascular occlusions
Daily ConversationUniversity Students
คำศัพท์และข้อสังเกตด้านการพูดสำหรับบทเรียนนี้
บทเรียนฝึกพูดนี้ใช้วิดีโอ “CumbriaMed Research Webinar Series: Obesity” เป็นสื่อ คำที่ถูกพูดซ้ำบ่อยที่สุด: weight, loss, obesity, drug, disease วิดีโอนี้มี 445 ประโยค และ 5460 คำ สำหรับฝึกพูดตาม ช่วงที่มีเสียงพูดยาว 46:14 ผู้พูดพูดด้วยความเร็วสม่ำเสมอ ประมาณ 118 คำต่อนาที เหมาะกับการฝึกพูดตาม มีเพียง 79% ของคำที่อยู่ใน 3,000 คำที่ใช้บ่อยที่สุดในภาษาอังกฤษ คำศัพท์จึงค่อนข้างยาก
คำศัพท์สำคัญในวิดีโอนี้
คำที่ควรเรียนรู้ 15 คำจากวิดีโอ พร้อมคำอ่านและความหมาย:
| คำศัพท์ | คำอ่าน | ความหมาย |
|---|---|---|
| diabetes คำนาม | /ˌdaɪəˈbiːtiːz/ | เบาหวาน |
| hormone คำนาม | /ˈhoɹmoʊn/ | ฮอร์โมน |
| kidney คำนาม | /ˈkɪdni/ | ไต, วักกะ |
| graph คำนาม | /ɡɹæf/ | กราฟ |
| dose คำนาม | /ˈdəʊ̯s/ | ขนาดยา |
| lifestyle คำนาม | /ˈlaɪfˌstaɪl/ | วิถีชีวิต, ไลฟ์สไตล์ |
| select คำกริยา | /sɪˈlɛkt/ | คัดเลือก |
| insulin คำนาม | /ˈɪnsəlɪn/ | อินซูลิน |
| pregnancy คำนาม | /ˈpɹɛɡnənsi/ | การตั้งครรภ์ |
| specialist คำนาม | /ˈspɛʃəlɪst/ | ผู้เชี่ยวชาญ |
| symptom คำนาม | /ˈsɪm(p)təm/ | อาการ |
| indicate คำกริยา | /ˈɪndɪˌkeɪt/ | บ่งบอก |
| tissue คำนาม | /ˈtɪʃ.(j)u/ | ทิชชู่ |
| physician คำนาม | /fəˈzɪʃən/ | หมอ, แพทย์ |
| consultant คำนาม | /kənˈsʌl.tənt/ | ที่ปรึกษา |
ไวยากรณ์ในวิดีโอนี้
โครงสร้างที่ผู้พูดใช้บ่อยที่สุด พร้อมคำพูดจริงจากวิดีโอ:
| โครงสร้าง | ในวิดีโอ |
|---|---|
| Present perfect continuous have/has been + -ing — การกระทำที่เริ่มก่อนหน้านี้และยังดำเนินอยู่ | We've been using · we've been working |
| Present perfect have/has + กริยาช่อง 3 — เหตุการณ์ในอดีตที่ยังเกี่ยวข้องกับปัจจุบัน | has heard · we've listed · have only had |
| Passive voice be + กริยาช่อง 3 — เน้นสิ่งที่เกิดขึ้น ไม่ใช่ผู้กระทำ | are associated · is secreted · is known |
| Relative clauses who / which + อนุประโยค — ข้อมูลเพิ่มเติมเกี่ยวกับคนหรือสิ่งของ | glucagon, which is · version, which is · Semaglutide, which is |
การออกเสียงที่ควรระวัง
ผู้พูดใช้รูปย่อและรูปลดเสียง 41 ครั้ง เช่น we've, I'm, I'd ให้พูดแบบสั้นตามที่ได้ยิน
- เสียง “sh” และ “zh”: reduction /ɹɪˈdʌk.ʃən/, essentially /ɪˈsɛnʃəli/, medication /mɛdɪˈkeɪʃən/, specialist /ˈspɛʃəlɪst/, tissue /ˈtɪʃ.(j)u/
- คำยาว — ลงเสียงหนักให้ถูกพยางค์: obesity /ə(ʊ)ˈbiːsɪti/, essentially /ɪˈsɛnʃəli/, cardiovascular /ˌkɑːdi.əʊˈvæskjʊlə(ɹ)/, imperial /ɪmˈpɪɹ.i.əl/, medication /mɛdɪˈkeɪʃən/
เสียงที่คนไทยมักออกเสียงยาก:
- เสียงท้ายคำ — ออกเสียงให้ครบ ไม่เปลี่ยนเป็นตัวสะกดแบบไทย: diabetes /ˌdaɪəˈbiːtiːz/, referral /ɹɪˈfɜː.ɹəl/, graph /ɡɹæf/, versus /ˈvɝsəs/, dose /ˈdəʊ̯s/
- /v/ — ไม่ใช่ /w/ ให้ฟันบนแตะริมฝีปากล่าง: cardiovascular /ˌkɑːdi.əʊˈvæskjʊlə(ɹ)/, versus /ˈvɝsəs/, overweight /ˌoʊvɚˈweɪt/, prevalence /ˈpɹɛvələns/, behavioral /bɪˈheɪvjəɹəl/
- /z/ — เสียงก้อง ไม่ใช่ /s/: diabetes /ˌdaɪəˈbiːtiːz/, physician /fəˈzɪʃən/, horizon /həˈɹaɪ.zən/, combinations /kɑmbɪˈneɪʃənz/, glucose /ˈɡluː.kəʊz/
วิธีฝึกกับวิดีโอนี้
- ฟังวิดีโอให้จบหนึ่งรอบโดยยังไม่ต้องพูด แล้วจดคำที่ยังไม่รู้จัก
- พูดตามทีละประโยคด้วยความเร็วปกติ ทำซ้ำแต่ละประโยคจนจังหวะของคุณตรงกับผู้พูด
- อัดเสียงตัวเองแล้วเทียบกับต้นฉบับ โดยสังเกตคำอย่าง diabetes, hormone, kidney เป็นพิเศษ
เทคนิค Shadowing คืออะไร?
Shadowing เป็นเทคนิคการเรียนรู้ภาษาที่ได้รับการรับรองทางวิทยาศาสตร์ พัฒนาขึ้นสำหรับการฝึกนักแปลมืออาชีพ วิธีการนี้เรียบง่ายแต่ทรงพลัง: คุณฟังเสียงภาษาอังกฤษจากเจ้าของภาษาและพูดตามทันที — เหมือนเงาที่ตามผู้พูดด้วยช่วงเวลาห่าง 1-2 วินาที การวิจัยแสดงว่าเทคนิคนี้ปรับปรุงความแม่นยำในการออกเสียง ทำนองเสียง จังหวะ การเชื่อมเสียง การฟังเข้าใจ และความคล่องแคล่วในการพูดได้อย่างมีนัยสำคัญ